Frontier Publications
- Keep 'em un-coordinatedCoordinated effects in mergersBulletin | 19.08.2010.
- The times, they’re a changin’Using economics to adapt to climate changeBulletin | 11.08.2010.
- Taking the strain Risk-sharing in UK rail frachisingBulletin | 01.08.2010.
- Necessary inventionsEconomic policies to increas low-carbon innovationBulletin | 15.07.2010.
- Economic Analysis of the RSPTWith a postscript on the negotiated outcomePaper | 05.07.2010.
- Not patently obviousHolders of patents and the Australian Trade Practices ActBulletin | 30.06.2010.
- Shelf lifeUsing promotions effectivelyBulletin | 10.06.2010.
- RPI-X@20: Output measures in the future regulatory frameworkA report prepared for OfgemPaper | 31.05.2010.
- RPI-X@20: The future role of benchmarking in regulatory reviewsA final report prepared for OfgemPaper | 31.05.2010.
- Public competitionThe choices facing the UK government after the electionBulletin | 29.04.2010.
A different remedy
Assessing mergers in the pharmaceutical industryThe UK competition authorities recently cleared a healthcare merger resulting in a combined market share in excess of 90% for one of the relevant products, merely imposing a temporary price cap. This seemed to mark a departure from the European Commission's approach to pharmaceutical merger cases, and its tendency to seek product divestments if market shares exceeded 40-50%. The explanation lies in the role of regulation and buyer power in the UK health service, which featured prominently in the UK decision. In this bulletin, we expore the implications.
 frontier bulletin - a different remedy.pdf |
 Printer friendly |